Showing 781 - 800 results of 228,202 for search '(( 2 d decrease ) OR ( 10 ((ng decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.57s Refine Results
  1. 781

    MBCD decreased stemness in MDA-MB-231. by Ankit Sharma (578833)

    Published 2019
    “…Densitometry analysis was shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0209435#pone.0209435.s002" target="_blank">S1C Fig</a>.…”
  2. 782
  3. 783
  4. 784
  5. 785
  6. 786
  7. 787

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…We projected long-term clinical and economic outcomes of immediate ART initiation in Côte d’Ivoire.</p><p>Methods</p><p>We used a mathematical model to compare three potential ART initiation criteria: 1) CD4 <350/μL (<i>ART<350/μL</i>); 2) CD4 <500/<i>μ</i>L (<i>ART<500/μL</i>); and 3) ART at presentation (<i>Immediate ART</i>). …”
  8. 788
  9. 789
  10. 790
  11. 791
  12. 792

    Decreased expression of CD1d in highly metastatic murine and human breast cancer cells. by Laura M. Hix (217695)

    Published 2011
    “…(B) Flow cytometry analysis of CD1d using a PE-conjugated anti-CD1d mAb (1B1) or isotype IgG2b control. …”
  13. 793
  14. 794
  15. 795
  16. 796
  17. 797
  18. 798
  19. 799

    Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

    Published 2025
    “…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10<sup>−42</sup>, condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10<sup>−21</sup>, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10<sup>−39</sup>, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10<sup>−26</sup>, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”
  20. 800

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease by Sandra L. Dabora (206838)

    Published 2011
    “…The remainder had stable disease (47.2%, 17/36), or were unevaluable (8.3%, 3/36). The mean decrease in kidney tumor size (sum of the longest diameters [sum LD]) was 29.9% (95% CI, 22 to 37; n = 28 at week 52). …”